PD-1/PD-L1抑制剂在结直肠癌治疗中的现状及预后预测

被引：24

作者：

田若曦 ^{[1
]}

孟泽松 ^{[2
]}

王贵英 ^{[2
]}

王光林 ^{[2
]}

王飞飞 ^{[2
]}

姚庆斌 ^{[1
]}

机构：

[1] 天津医科大学基础医学院

[2] 河北医科大学第四医院外二科

来源：

肿瘤 | 2020年 / 40卷 / 03期

关键词：

结直肠肿瘤; 抗肿瘤药,免疫学; B7-H1抗原; 预后;

D O I：

暂无

中图分类号：

R735.34 [];

学科分类号：

摘要：

结直肠癌(colorectal cancer,CRC)死亡率在世界范围内居第4位,是癌症相关死亡的一个重要原因,严重威胁患者的生存及生活质量。手术、化疗和放疗是CRC的主要治疗手段,但CRC患者的总生存率却没有显著提高,亟待寻找新的治疗手段。肿瘤免疫逃逸在肿瘤增殖、复发和转移过程中发挥着关键作用。免疫检查点程序性死亡受体1(programmed death-1,PD-1)及其配体1(programmed death-ligand1,PD-L1)在肿瘤免疫逃逸中发挥着重要作用,抗PD-1/PD-L1治疗在癌症治疗中成为研究热点。越来越多的研究提示,抗PD-1/PD-L1免疫治疗在微卫星高度不稳定(microsatellite instability-high,MSI-H)CRC治疗中已取得显著疗效。因此,本研究就抗PD-1/PD-L1疗法在CRC患者中的临床应用,以及改善其低反应率的各种策略进行了总结,并对肿瘤细胞表面PD-L1表达水平在CRC预后中的预测价值进行综述。

引用

页码：215 / 222

页数：8

共 15 条

[1]

PD-1/PD-L1抑制剂联合其他方式治疗在非小细胞肺癌治疗中的研究进展 [J].

乔梦 ;

蒋涛 ;

赵沙 ;

周彩存 .

肿瘤, 2017, 37 (06) :663-669

[2]

Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer[J] Jacqueline N. Chu MD;Jin Choi BS;Sassan Ostvar PhD;James A. Torchia MD; PhD;Kerry Lynn Reynolds MD;Angela Tramontano MPH;Justin F. Gainor MD;Daniel C. Chung MD;Jeffrey W. Clark MD;Chin Hur MD; MPH Cancer 2019,

[3]

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies[J] Shetal A. Patel;Andy J. Minn Immunity 2018,

[4]

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients[J] V. Gopalakrishnan;C. N. Spencer;L. Nezi;A. Reuben;M. C. Andrews;T. V. Karpinets;P. A. Prieto;D. Vicente;K. Hoffman;S. C. Wei;A. P. Cogdill;L. Zhao;C. W. Hudgens;D. S. Hutchinson;T. Manzo;M. Petaccia de Macedo;T. Cotechini;T. Kumar;W. S. Chen;S. M. Reddy;R. Szczepaniak Sloane;J. Galloway-Pena;H. Jiang;P. L. Chen;E. J. Shpall;K. Rezvani;A. M. Alousi;R. F. Chemaly;S. Shelburne;L. M. Vence;P. C. Okhuysen;V. B. Jense

[5]

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label; multicentre; phase 2 study[J] Michael J Overman;Ray McDermott;Joseph L Leach;Sara Lonardi;Heinz-Josef Lenz;Michael A Morse;Jayesh Desai;Andrew Hill;Michael Axelson;Rebecca A Moss;Monica V Goldberg;Z Alexander Cao;Jean-Marie Ledeine;Gregory A Maglinte;Scott Kopetz;Thierry André The Lancet Oncology 2017,

[6]

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer[J] Yohei Masugi;Reiko Nishihara;Juhong Yang;Kosuke Mima;Annacarolina da Silva;Yan Shi;Kentaro Inamura;Yin Cao;Mingyang Song;Jonathan A Nowak;Xiaoyun Liao;Katsuhiko Nosho;Andrew T Chan;Marios Giannakis;Adam J Bass;F Stephen Hodi;Gordon J Freeman;Scott Rodig;Charles S Fuchs;Zhi Rong Qian;Shuji Ogino Gut 2017,

[7]

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J] Dung T. Le;Jennifer N. Durham;Kellie N. Smith;Hao Wang;Bjarne R. Bartlett;Laveet K. Aulakh;Steve Lu;Holly Kemberling;Cara Wilt;Brandon S. Luber;Fay Wong;Nilofer S. Azad;Agnieszka A. Rucki;Dan Laheru;Ross Donehower;Atif Zaheer;George A. Fisher;Todd S. Crocenzi;James J. Lee;Tim F. Greten;Austin G. Duffy;Kristen K. Ciombor;Aleksandra D. Eyring;Bao H. Lam;Andrew Joe;S. Peter Kang;Matthias Holdhoff;Ludmila Danilova;Lesli

[8]

Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer[J] Kyu Sang Lee;Yoonjin Kwak;Soyeon Ahn;Eun Shin;Heung-Kwon Oh;Duck-Woo Kim;Sung-Bum Kang;Gheeyoung Choe;Woo Ho Kim;Hye Seung Lee Cancer Immunology; Immunotherapy 2017,

[9]

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre; single-arm; phase 2 study[J] Van K Morris;Mohamed E Salem;Halla Nimeiri;Syma Iqbal;Preet Singh;Kristen Ciombor;Blase Polite;Dustin Deming;Emily Chan;James L Wade;Lianchun Xiao;Tanios Bekaii-Saab;Luis Vence;Jorge Blando;Armeen Mahvash;Wai Chin Foo;Chimela Ohaji;Manolo Pasia;Gail Bland;Aki Ohinata;Jane Rogers;Amir Mehdizadeh;Kimberly Banks;Richard Lanman;Robert A Wolff;Howard Streicher;James Allison;Padm

[10]

Cancer Statistics; 2017[J] Rebecca L. Siegel MPH;Kimberly D. Miller MPH;Ahmedin Jemal DVM; PhD CA: A Cancer Journal for Clinicians 2017,

← 1 2 →